By Giovanna Verginelli Mezher

The Public Consultation (CP) No. 1.316/2025, which aims to initiate the review process of Collegiate Board Resolution (RDC) No. 327/2019 from the … Medicinal Cannabis Review: Public Consultation 1.316/2025 open

We are pleased to announce our collaboration on the Chambers and Partners Life Sciences 2025 Global Practice Guide! Our partners Priscila Kashiwabara … Life Sciences Brazil Global Guide 2025 | Chambers & Partners

On December 24, 2024, Law No. 15,070 of December 23, 2024 (“Bioinputs Law”), which regulates the production, use, and commercialization of bioinputs … Bioinputs Law: A new regulatory framework for sustainable agriculture in Brazil

The newly implemented regulatory framework governing food safety and quality in Brazil took effect on September 1st, 2024. The Collegiate Board Resolutions … Brazil Implements a New Regulatory Framework for Food Products

We are pleased to announce our collaboration on the Chambers and Partners Life Sciences 2024 Global Practice Guide! Our partners Priscila Kashiwabara … Life Sciences’ Brazil Global Guide 2024 is now available

Anvisa approved the new simplified regulation for the registration of biosimilar medicines, whose publication in the Official Gazette (DOU) is still awaited. … New Regulation Approved by Anvisa Simplifies the Registration Process for Biosimilar Medicines

Anvisa recently launched a public notice with the aim of selecting Startups involved in the research and development of medicines, in order … Anvisa opens its doors to Startups: Stepping towards Innovation in Medicines

Kasznar Leonardos is proud to be a contributor to the Legal 500’s “Brazil: Life Sciences” guide. Our partners Priscila Kashiwabara and Viviane … Kasznar Leonardos contributes to the “Brazil: Life Sciences” guide by The Legal 500

On December 26, 2023, Decree No. 68,233/2023 was published in the Official Gazette of São Paulo, regulating the free provision of cannabidiol … Decree regulates the free provision of cannabidiol-based medications by the Unified Health System of São Paulo

ANVISA’s new Regulatory Agenda 2024-2025 (RA 24/25) was approved and published on the Official Gazette on December 18th. The Joint Ordinance No. … 2024-2025 Regulatory Agenda Has Been Approved by the Brazilian FDA

The number of Brazilians using medicinal cannabis-based medications increased by approximately 165% in one year, representing a jump from 188,000 to 430,000 … Increase in Patients Using Medicinal Cannabis and Its Consequences

Starting February 6, 2024, generic and branded-generic (“similar”) drugs will be allowed to have different labels than their respective standard labels with … Anvisa approves skinny labeling practice in Brazil

On October 19, 2023, the Federal Official Gazette (DOU) published Administrative Order 1,184/2023, which provides for the National Health Surveillance Agency’s (Anvisa) … ANVISA’s Personal Data Protection Policy is released

The chapter “Pharma & Medical Device Regulation,” authored by our partners Claudio Barbosa, Viviane Trojan and attorney at law Giovanna Mezher, has … Lexology GTDT – Pharma & Medical Device Regulation 2024

The National Health Surveillance Agency (ANVISA) has approved the opening of a Public Consultation to amend the regulation of biosimilar medicines in Brazil … Green light from ANVISA regarding the registration of biosimilar medicines in Brazil